Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2970544 | The Journal of Heart and Lung Transplantation | 2013 | 5 Pages |
Abstract
This report provides data on estimated safety and efficacy of bivalirudin and epoprostenol as an AT strategy in pediatric patients on extended VAD support. The short drug half-life and predictable AT response facilitated conversion to standard AT regimens at the time of transplantation (heparin-induced thrombocytopenia-negative patients). These agents should be considered for management of pediatric VAD patients when standard regimens fail.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jennifer M. MD, Sujata MD, M. Patricia MD, Holger MD, David B. MD, Umesh MD,